Company intelligence / Profile preview

Rytvel Biotechnology

Sainte-Marthe-sur-le-Lac, Quebec, Canadaca.linkedin.com ↗

Ownership: Private
Development stage: Other

Overview

Rytvel Biotechnology has been involved in the development and evaluation of a novel anti-interleukin 1 beta receptor modulator aimed at reducing the impact of preterm birth on neurovascular health. The available information suggests activity at the preclinical or translational research level, with no published clinical trial results to date.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Rytvel Biotechnology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rytvel Biotechnology.

Explore the full profile